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A solvent detergent treated fibrinogen was purified from human plasma by
cryoprecipitation (cryo) followed by chemical precipitation using ethanol (EtOH) or
ammonium sulfate (AS) as precipitating agents. Amounts of fibronectin (FN), factor XIII
A-subunit (FXIIIA), factor XIII b-subunit (FXIIIB), and alpha2-antiplasmin (α2-AP) in
the isolated fibrinogen were quantified. Thromboelastography (TEG) analysis was used
to evaluate the clot strength of the isolated fibrinogen and to determine the ability of the
ethanol and ammonium sulfate precipitations to eliminate the solvent detergent. Sodium
dodecylsulfate-polyacrylamide gel analysis indicated that fibrinogen produced by each of
these precipitation methods had similar purity. Quantitative western blot analysis
revealed that fibrinogen produced by ammonium sulfate precipitation contained increased
amounts of FN, FXIIIB, and α2-AP. TEG analysis showed that ammonium sulfate
precipitated fibrinogen yielded a fibrin clot with the highest maximal strength. In
addition, a single ethanol precipitation was sufficient to remove the solvent detergent
while a single ammonium sulfate precipitation was not effective in removing the solvent
detergent mixture Tri (n-butyl) phosphate (TNBP) and Triton X-100 as judged by the
ability of the material to form a clot.
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INTRODUCTION
Fibrinogen
Fibrinogen (FI) is a central molecule in the blood coagulation cascade that is
transformed by thrombin into fibrin which polymerizes forming a clot to prevent the loss
of blood at the site of vascular injury. Furthermore, because it has multiple binding sites
that can react with other proteins, fibrinogen plays important roles in many physiological
and pathological processes including blood clotting, fibrinolysis, cell adhesion,
inflammation, angiogenesis, atherogenesis, tumorigenesis, and wound healing [1].
Fibrinogen is a 340 kDa glycoprotein consisting of two identical subunits, each of which
is made of three polypeptide chains termed Aα, Bβ, and γ [2]. The three chains of
fibrinogen differ in terms of their structures and functions [Table 1].
A series of disulfide bonds link fibrinogen polypeptide chains forming elongated
45 nm tri-nodular structures with distinct domains. These domains are arranged into three
main structural regions: a central E, two distal D and the αC regions [3-5]. The central E
nodule is formed by the N-terminal portions of the six polypeptide chains. The distal D
nodules, formed by the C-terminal portions of the Bβ and γ as well as a fraction of the Aα
chains, are separated from the E region by coiled-coil regions [6, 7]. The C-terminal
region of the Aα-chain extends out from the D domains and is called the αC domains [8].
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Table 1: Properties of fibrinogen chains
α-chain
67 KDa
Molecular Weight
[9]
Amino Acids [2]
610
FpA
Fibrinopeptide
None
Carbohydrate
[10,11]

β-chain
54 KDa

γ-chain
47 KDa

461
FpB
2 oligosaccharide

411
None
2 oligosaccharide

Based on the composition of the γ-chain, human fibrinogen can be isolated into
two major fractions, fibrinogen-1 and fibrinogen-2 [12, 13]. Fibrinogen-1 possesses two
homo-dimeric γ-chains each composed of 411 amino acids while fibrinogen-2 contains
two hetero-dimeric molecules one γ-chain and one γ -chain [12, 14]. The γ -chain
accounts for 15% of plasma fibrinogen and is formed by the alternative processing at the
exon 9-exon 10 boundaries of the primary mRNA transcript [15]. The inclusion of intron
9 in the messenger results in the replacement of 4 amino acids (AGDV) of the γ-chain
with a 20 amino acid sequence that contains two sulfated tyrosines and several Asp and
Glu residues. Therefore, the γ -chain is longer and contains more anion groups than the γchain [16, 14].
Fibrinogen has the ability to react with numerous substances with important
physiological consequences. For example, The C-terminal of the Aα-chain (αC domains)
of fibrinogen has binding sites for α2-AP, plasminogen, tissue-type plasminogen activator
(tPA), and PAI-2. Table 2 lists binding sites and physiological roles of some fibrinogenprotein interactions.
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Table 2: Fibrinogen binding Ligands
Ligands
Binding Site

Function

Fibronectin [17]

Aα-chain

Cell adhesion

FGF-2, bFGF [18]

-

Lipoprotein (a) [19, 20]

Aα-chain

Proliferation of endothelial
cells
Inhibit fibrinolysis

Thrombin [21]

γ -chain

Fibrinopeptide release

Plasminogen [22]

Aα-chain

Enhance fibrinolysis

FXIII [23-25]

γ -chain

Stabilizing clot

α2-AP [26]

Aα-chain

Resist fibrinolysis

Integrin [2]

Aα-chain

Cellular interactions

Calcium [27]

Bβ and γ-chains

Promote polymerization

Human fibrinogen heterogeneity results from modification at several different
sites both during and after biosynthesis. The heterogeneity arises from alternative splicing
[28], alteration of different amino acids by sulfation [29], phosphorylation [30], various
degrees of glycosylation [31], proteolysis [32], and some genetic polymorphisms [33].
These mechanisms form over a million species of fibrinogen [34].These heterogeneities
can change fibrin matrix properties thus helping to explain the difference that exist
between individuals and wound healing.
During coagulation, thrombin converts soluble fibrinogen into fibrin monomers,
which then polymerize to form a network of fibrin fibers. This network is stabilized by
thrombin activated FXIII to form an insoluble fibrin clot. Formation of fibrin begins
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when thrombin binds to a substrate site in fibrinogen and cleaves fibrinopeptides A (FpA)
and B (FpB) from the amino termini of the Aα and Bβ chains, respectively. The removal
of FpA exposes the polymerization site “A” that contains the N-terminal sequence (GlyPro-Arg-Val) of the Aα-chain, while the removal of FpB exposes the polymerization site
“B” that contains the N-terminal sequence of the Bβ-chain [35]. The polymerization site
“A” interacts with the complementary binding site of the γ-chain, whereas the
polymerization site “B” interacts with the complementary binding site of the β chain [36].
These interactions lead to the formation of half-staggered, double-stranded protofibrils
that undergo lateral aggregation to form fibers [37]. Thrombin simultaneously converts
factor XIII (FXIII) to the active form (FXIIIa) which catalyzes formation of covalent ε(γ-glutamyl) lysine bonds between adjacent fibrin molecules [37-40]. The cross-linking
occurs rapidly between Lys-406 of one γ-chain and Gln-398 of another γ-chain to form γdimers [41, 42, 25]. In addition, hetero-dimers cross-linked α-γ have been found in
plasma fibrinogen [43]
Different techniques have been developed for the purification of fibrinogen from
plasma materials. Cryoprecipitation is the most common method for isolating fibrinogen,
which reduces the solubility of fibrinogen at lower temperature to prevent its
denaturation. Compared to fresh frozen plasma, cryoprecipitate contains an increased
percentage of fibrinogen. Cryoprecipitation involves freezing the citrated plasma at lower
temperature, usually -20 °C or less for at least 12 hours. The frozen plasma is slowly
thawed at 4 °C followed by centrifugation to isolate the fibrinogen precipitate. The
concentration of fibrinogen produced by cryoprecipitation is between 8 to 30 mg/ml and
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can be increased to 40 to 60 mg/ml using repeated freeze/thaw cycles [44]. An
ultrafiltration procedure has been used to purify fibrinogen where platelet rich plasma is
separated using an ultrafiltration chamber with a molecular weight cutoff of 30 kDa.
Fibrinogen obtained using this method has a final concentration of 6 mg/ml and lower
clottability due to large amount of fibrinogen being denatured [45]. Fibrinogen has also
been isolated from human plasma by using chemical precipitation methods in which
chemical agents such as ethanol, glycine, β-alanine, ether, or ammonium sulfate are used
to precipitate fibrinogen from plasma [46-49].
The clinical use of fibrinogen from pooled human plasma has been previously
associated with a high risk of transmission of plasma–borne infectious species such as
HIV, HBV, and HCV. The improvements in viral testing and screening have reduced, but
not eliminated this risk. Therefore, different techniques have been developed in order to
inactivate pathogenic viruses in fibrinogen derived from human plasma. Dry heat
treatment at 60-68 °C of plasma cryoprecipitate inactivates HIV but it does not prevent
the transmission of HCV [50]. Plasma pathogens have been inactivated by treating fresh
plasma with methylene blue followed by exposure to visible light. This approach is less
effective versus non-enveloped viruses and results in approximately 20% fibrinogen loss
[51]. Solvent detergent (SD) treatment is the most effective procedure for inactivating
blood-borne lipid-enveloped viruses. Solvent detergent treatment inactivates viruses by
dissolving their lipid envelope but it does not inactivate non-lipid enveloped viruses such
as parvovirus or hepatitis A virus [50].

The treatment of cryoprecipitate with a

combination of organic solvent, tri (n-buty1) phosphate (TNBP), and detergent (sodium
cholate, Tween 80, or Triton X-100) has been shown to inactivate very large quantities of
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HBV, HCV, and HIV while preserving the activity of the purified protein. Radosevich et
al [52] showed that treating cryoprecipitate with a mixture of 0.3% TNBP and 1% tween
80 at 25 °C for 6 hours inactivated

5.5 log10 of HIV,

5 log10 of VSV virus, and

6.5

log10 of sindbis virus. Horowitz and coworkers [53] revealed that subjecting pooled
plasma to a mixture of 1% TNPB and 1% Triton X-100 for 4 hours at 30 °C inactivates
106 CID50 of HBV, 105 CID50 of HCV, and 106.2 TCID50 of HIV.

Factor XIII
Factor XIII, activated in the latter stages of the blood coagulation cascade, is a
pro-transglutaminase that exists naturally in an intracellular or plasma form [54, 55]. The
plasma form is a tetramer composed of two A-subunits (FXIIIA) and two B-subunits
(FXIIIB) with a molecular mass of

83 and ~80 kDa respectively [56]. Structural

investigation of the tetramer indicates that the two A-subunits are globular proteins
surrounded by two long flexible B-subunits [57, 58]. There are non-covalent interactions
between the two A-chains and appears to be a non-covalent bond between the A and B
[59]. The A-subunit contains the active site of the enzyme while the B-subunit serves to
transport and protect the catalytic A-subunit until it is required in catalysis [60, 61].
Under normal conditions, the human plasma concentration of FXIII is ~14 to 28 mg/L
[62]. Whereas carbohydrate accounts for approximately 8.5% of the total molecular
weight of FXIIIB, the FXIIIA contains no carbohydrate [Table 3].
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Table 3: Characteristics of FXIII subunits
A-subunit
Molecular weight [56]
83 kDa
Residues [63, 64]
731
Carbohydrate [65]
None
N-terminal [59]
Acetylated serine
Disulfide bonds [63]
None
Structure [64]
Globular
Function [66]
Catalyzes an acyl transfer
reaction
Secreted by [66]
Liver, monocytes
and megakaryocytes
Active site [66]
Cys314

B-subunit
80 kDa
641
~8.5% of the total weight
Glutamic acid
20
Kinked strand
Acts as a carrier for
A-subunit
Liver
None

The primary structure of FXIII subunits has been determined through the aid of
amino acid sequence analysis and cDNA cloning. The A-subunit is made of five distinct
folded domains: an activation peptide of 37 amino residues that is cleaved off during
thrombin activation of the enzyme, a β-sandwich containing residues 38-183, a catalytic
core composed of residues 184-515, and two barrels comprised of residues 516-627 and
628-731, respectively [66]. While the catalytic core consists of both α-helices and βsheets, the β-sandwich and barrel domains contain only β-sheets [Fig 1]. There are
several hydrogen bonds and salt bridges between the β-sandwich, the activation peptide,
and the catalytic core of the first subunit with the β-barrel and catalytic core of the second
subunit [67]. These non-covalent interactions help stabilize the overall structure.
Although FXIIIA possesses nine cysteine residues, no disulfide bridges have been
detected in the subunit. There are six potential N-glycosylation sites in FXIIIA but no
carbohydrate residue has been found in the secondary structure [65].
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FXIIIB is a modular protein built from 10 repetitive sushi domains. Each sushi
domain contains approximately 60 amino acids held together by two disulfide bridges
forming a β-sandwich tertiary structure [63]. Employing electron microscopy and
sedimentation techniques, the B-subunit appears as a thin, flexible strand with random
kinks whereas unbound FXIIIB appears as a monomeric structure [64].
While plasma FXIII (pdFXIII) circulates as a tetramer, intracellular FXIII is a
dimer composed of two A-subunits (FXIIIA2) each containing 730 amino acid residues
[68]. This dimeric molecule has a molecular weight of approximately 160 kDa and
mainly found in platelets, monocytes, and megakaryocytes [68, 63]. The primary
structure of cellular FXIII is identical to plasma FXIIIA and the two molecules share the
same immunochemical and electrophoretic properties
FXIIIA catalyzes an acyl transfer reaction where glutamine residues serve as an
acyl donor. This reaction proceeds through acylation and de-acylation intermediate steps
to form an amide bond between -carbonyl group of glutamine and -amino group of
lysine [69]. Compared to other transglutaminase family members, FXIIIA has more
restricted substrate specificity.
In the final stage of the blood coagulation cascade, the serine protease thrombin
activates either form of FXIII in the presence of Ca2+. The activation sequence begins
when thrombin hydrolyzes the peptide bond at Arg37-Gly38 releasing the activation
peptide from the N-terminal region of the FXIII [69, 70] [Fig 1]. Studies using radio
crystallography showed that the released activation peptide did not bind thrombin but
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remained attached to the FXIII molecule preventing the access of the substrate to the
active site [58]. The activation sequence proceeds when Ca2+ binds to either the free
activation peptide or the zymogen. This binding induces a conformational change that
leads to the dissociation of the activated A-subunits from the B-subunits. As a result, the
active site Cys-314 that was originally shielded by the activation peptide becomes
unmasked and available for reaction [60, 71].

B

B
A

A´

A

Thrombin

B

A´

Ca2+

A´

A´

B

A2 *

Activation
Peptides

B

B

Figure 1: Schematic diagram illustrates FXIII activation in plasma. Removal
of the activation peptide by thrombin weakens the binding of B-subunit to the truncated
FXIIIA (
). Conformational change induced by Ca2+ causes dissociation of
to
generate FXIIIa [72].
Except for the dissociation of the B-subunit step, intracellular FXIII activation by
thrombin follows the same mechanism as extracellular FXIII. Activation of intracellular
FXIII is faster since the B-subunit of plasma FXIII suppresses activation of cellular FXIII
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by thrombin thereby down-regulating pdFXIII cross-linking of fibrinogen [73]. The
presence of fibrin speeds up the activation of pdFXIII by approximately one hundredfold
[71, 74]. This is because the adsorption of thrombin and pdFXIII onto the fibrin (ogen)
surface orient these molecules in a way that favors the hydrolysis of the peptide bond at
Arg37-Gly38 by thrombin. Therefore, fibrin facilitates the activation of extracellular
FXIII while the absence of B-subunit from intracellular FXIII inhibits fibrin catalysis
[74].
The B-subunit of FXIII binds to the

-chain of fibrinogen thus heterodimeric

fibrinogen (fibrinogen 2, γ/ ) serves as a carrier for FXIII in blood and also regulates its
activity [75]. The presence of FXIII with fibrinogen in the plasma ensures that the
formation of fibrin is associated with FXIII mediated cross-linking to generate a strong
clot. FXIII cross-links homo-dimeric fibrinogen 1 molecules (γ/γ) 3.5 times faster than
hetero-dimeric fibrinogen 2 molecules (γ/ ) indicating that fibrinogen 2 bound FXIII is
essential for inhibiting FXIII mediated cross-linking activity in plasma [74]. Fibrinogen
also reduces the amounts of calcium required to activate the truncated FXIIIA dimer
(FXIII

). Besides thrombin, there are several other serine proteases such as

endogenous platelet acid and calpain that can also activate FXIII by cleaving the Arg37Gly38 peptide bond [76, 77].
Besides fibrin and α2-antiplasmin, FXIIIA has many other potential substrate such
as plasminogen, lipoprotein (a), plasminogen activator inhibitor type 2 (PAI-2),
thrombin-activatible fibrinolysis inhibitor (TAFI), fibronectin, and many other proteins
[Table 4].
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Table 4: FXIII substrates
Substrate
Cross-linking Site

Function

Gln2

Cross-linking
Targets
Lys303 of α-chain

Fibrin (ogen)

Gln221 and 237

Itself and γ-chains

Clot stabilization

α-chain [81-83]

Lys208-Lys606

Fibrin (ogen)

Gln398, Gln399 and Itself and α-chains

Clot stabilization

γ-chain [23-25]

Lys406

Fibronectin [84, 85]

Gln3

α2-antiplasmin [78-

Inhibit fibrinolysis

80]

Itself, fibrin, and
collagen

Collagen [84, 86]

Gln3

Fibronectin, and

Wound healing;
migration of cells
into the clot
Stabilization of
extracellular matrix

fibrin
Gln3

Fibrin, collagen

Platelet adhesion to
the clot

Vitronectin [89, 90]

Gln93

Fibrin, collagen

Factor V [91, 92]

-

-

Thrombospondin

-

Fibrin

Platelet adhesion to
the clot
Increased thrombin
generation at the colt
surface
Platelet adhesion to
the clot

Actin [94, 95]

-

Fibrin

TAFI [96]

Gln2, Gln5, Gln292 Itself, fibrin

PAI-2 [97, 98]

-

Von Willebrand
Factor [87, 88]

[93]

Lys148, Lys230,
Lys413 of fibrin αchain

Clot reaction,
stabilization of the
platelet cytoskeleton
Resistance to
fibrinolysis
Resistance to
fibrinolysis

12

FXIII has important physiological roles in hemostasis, angiogenesis, wound
healing, and pregnancy [99, 100]. Plasma FXIII, also known as fibrin stabilizing factor, is
essential for preserving hemostasis by performing the following functions: Increasing clot
strength by cross-linking fibrin; inhibiting fibrinolysis by cross-linking α2-antiplasmin to
the α-chain of fibrin; inhibiting fibrinolysis by interfering with the adsorption of
plasminogen into fibrin surface. FXIII is critical for creating a rigid, strong, and elastic
clot needed to stop bleeding; therefore, FXIII deficiency results in severe bleeding [101104]. FXIII also plays a central role in the events that lead to wound healing such as
fibroblast proliferation, attachment of cells to substrate, and in collagen formation [105].
Studies showed that FXIII-deficient individuals have lower fibroblast growth rate than
patients with normal FXIII [105, 106]. FXIII activates a series of biochemical reactions
that assist in cell adhesion and without FXIII cells lose their regular shape due to cell
contact inhibition. In addition, collagen is not produced in the absence of FXIII which
delays wound healing [107].
Recombinant FXIIIA (rFXIII), which has similar structure and function as FXIIIA2, has been expressed in different cell types that include Escherichia coli [108],
Sacharomyces cerevisiae [109, 110], and Schizosacharomyces pombe [111]. The
numerous rFXIII crystal structures provided a wealth of information on catalytic activity
as well as enzyme activation. Moreover, this structural information has been used to
explain the consequences of some FXIII mutations [112].
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Alpha2-antiplasmin
Human alpha2-antiplasmin is the primary physiological inhibitor of the blood
fibrinolytic plasmin. α2-AP is secreted by the liver as a single-chain glycoprotein of 464
amino acid residues and molecular weight of ~70 kDa with

methionine as the N-

terminus (Met- α2AP) [113, 114]. The plasma concentration of α2-AP is ~70 µg/ml with a
half-life of 2.6 days [115-117]. During circulation, Met-α2AP undergoes proteolytic
cleavage between Pro12-Asn13 by circulating anti-plasmin cleaving enzyme (APCE), a
proline-specific serine protease [118]. This results in the formation of a 452 amino acid
derivative with N-terminal asparagine (Asn-α2AP). Asn-α2AP has a molecular weight of
~64 KDa and accounts for 70% of the α2-AP in plasma while Met- α2AP accounts for the
remaining 30% [113, 114]. Some properties of Met- α2AP and Asn- α2AP are listed in
table 5. The human α2-AP gene is located on chromosome 17, specifically 17pter-p12 and
17p13, and contains 10 exons and 9 introns [119]. The complete primary structure of
human α2-AP has been deduced from the sequence of its cDNA.
Human α2-antiplasmin belongs to the serine protease inhibitor (serpin) family but
unlike other serpins, α2-AP has an extensive C-terminal sequence of approximately 50
amino acids that contains a number of lysine residues that are important for plasmin
inhibition and plasmin (ogen) binding [120]. In addition, the C-terminal region of α2-AP
contains an RGD tri-peptide sequence (Arg426-Gly-Asp) that is essential for cell
recognition and adhesion [121]. Using the RGD sequence, the C-terminal region of α2AP binds to endothelial cell integrins. With the aid of X-ray structure, the C-terminal of
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α2-AP is shown to be positioned in the proximity of the reactive loop and binds strongly
to the K1 and K4 domains of plasmin increasing the inhibitory effect of α2-AP [122-124].
Table 5: Properties of α2-antiplasmin
Met-α2AP
Molecular weight [113,
67 KDa
114]
Amino acids [113, 114]
464
N-terminal
Methionine
Percentage [113, 114]
30%
Binding to fibrinogen [118] Slower

Asn-α2AP
64 KDa
452
Asparagine
70%
3-13 times faster

Human α2-AP regulates the fibrinolysis process in three ways [125]:
I.
II.
III.

Inactivates plasmin by forming a complex with it [126].
Prevents plasminogen adsorption to fibrin surface [127, 128].
Increases fibrin resistant to fibrinolysis by cross-linking fibrin with the aid of
FXIII [129-131].

In plasma, α2-AP inactivates plasmin rapidly with a second order reaction rate of 2x10-7
mol-1 s-1 [132]. The reaction of Lys448 and Lys464 residues in the carboxyl-terminal of
α2-AP with 1-3 kringles of plasmin (ogen) changes the conformation of the Ser741 of
plasmin which then binds to Arg376 of α2-AP to form the inactive irreversible plasminα2AP complex [133, 134]. Moreover, Lys groups in both α2-AP and fibrin bind to the
same active sites in plasminogen thereby α2-AP competitively inhibits the binding of
plasminogen to fibrin. Free plasmin generated by tissue-type plasminogen activator in
plasma has a short half-life (~0.1 sec) due to the rapid inactivation by α2-AP, while
plasmin produced in fibrin surface has a relatively longer half-life (~10 to 100 sec)
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because it is only slightly inactivated by α2-AP [135]. This indicates the importance of
prior incorporation of α2-AP into fibrinogen for effective inhibition of fibrinolysis.
The cross-linking of α2-AP to fibrinogen by FXIII is the most effective way to
inhibit endogenous fibrinolysis concurrent with fibrin formation and caused by activation
of plasminogen-bound to fibrin [130, 136]. The cross-linking reaction occurs between
either Gln14 of Met-α2AP or Gln2 of Asn-α2AP and Lys303 of α-chain of fibrin. FXIII
catalyzes transfer of acyl groups donated by α2-AP to the acceptor amine groups of
fibrinogen. The cross-linking reaction of α2AP with fibrinogen progress rapidly to
reaches a maximum plateaus with only 20-30% of the available Lys303 active sites being
occupied [137-139]. This limited reactivity suggests that the reaction equilibrium favors
dissociation of the cross-linked product or Lys303 active sites are unavailable for crosslinking reaction [140]. Asn-α2AP cross-links fibrinogen 3-13 times faster than Met-α2AP.
Consequently, the ratio of the two forms of α2-AP plays a critical role in the regulation of
fibrinolytic process [118].
While the molecular mechanism of plasmin inhibition in solution is well
understood, the inhibition of plasmin on the fibrin surface still requires further studies. In
addition to plasmin inactivation, α2-AP also inhibits tissue-type plasminogen activator
(TPA) and urokinase. The physiological importance of α2-AP is best characterized by
issues encountered by individuals deficient in this inhibitor. These patients experience
uncontrolled fibrinolysis and recurrent severe hemorrhagic disorder [141, 142].
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Previous studies have shown that the content of α2-AP in plasma-derived
fibrinogen is substantial (1.2-1.8 moles α2-AP per mole pdFI), and that native FXIII
catalyze its cross-linking in circulation [143].

Fibronectin
Fibronectin is the second most abundant protein within the extracellular matrix
(ECM) mediating its interactions with variety of cells. Fibronectin is multifunctional
glycoprotein exists in a soluble form in plasma, and in an insoluble form in the ECM.
Plasma fibronectin (pdFN) is synthesized by hepatocytes and secreted into plasma where
it circulates at a concentration of approximately 300-400 µg/ml [144]. Cellular
fibronectin (cFN) is composed of covalently cross-linked multimers and synthesized by
different cell types including fibroblasts, endothelial cells, chondrocytes, synovial cells,
and myocytes [145].
Fibronectin is composed of two very similar polypeptides with a molecular
weight of 220-250 kDa [146-148]. The polypeptides are linked by inter-chain disulfide
bonds located close to the C-terminal region forming a dimer molecule [149, 150]. Using
rotary shadowing electron microscopy the polypeptides appear as flexible extended Vshaped molecules or compact globular molecules [151]. Each polypeptide is made of
multiple homologous modules called type I, II, and III (F1, F2, and F3) in series [152154]. There are 12 type I modules, two type II modules, and 15-17 type III modules,
which together accounts for ~90% of the fibronectin sequence. Type I modules contain
~45 amino acids held together by two disulfide bonds and located in the amino and
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carboxyl termini regions of each subunit. Type II modules are composed of ~60 amino
acids linked by two disulfide bonds and localized in the gelatin binding domain of the
subunit. Type III modules consists of ~90 amino acids that are clustered together in the
middle of the subunit and does not contain disulfide bonds [155]. The N-terminal region
of fibronectin consist of five type I modules whereas the C-terminal contains three type I
modules.
Fibronectin contains binding sites for different molecules that are localized along
the length of the monomer enabling fibronectin to play an important role in many
physiological processes [156]. Because it’s rich in Arg-Gly-Asp tri-peptide sequences,
fibronectin plays important roles in cell migration, growth, and differentiation [157].
Fibronectin incorporated into fibrin by FXIIII mediates interaction of fibrin with cells or
platelets during clot formation [158-160]. Bound fibronectin forms a three-dimensional
matrix at the wound site that attracts different cell types and extracellular matrix proteins
[161]. F1 (1-5) contains binding sites for heparin, fibrin, and cell surface proteins for
pathogenic bacteria such as streptococcus dysgalactiae that play a putative mechanism for
host by microorganism [162].
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PURIFICATION OF FIBRINOGEN FROM HUMAN PLASMA

We are employing a combination of physical and chemical precipitation methods
to purify relatively large amount of fibrinogen from human plasma for the purpose of
fibrin based bandages and expanding hemostatic foams. Virally inactivated fibrinogen
was isolated from human plasma using cryoprecipitation followed by ethanol or
ammonium sulfate precipitation. Fig 2 shows the major steps of the fibrinogen production
procedure. The aim of this study was to evaluate the ability of ethanol and ammonium
sulfate precipitation approaches to eliminate solvent detergent. We also estimated the
amount of fibronectin, factor XIIIA, factor XIIIB, and α2-antiplasmin in plasma
fibrinogen purified by the two different chemical precipitation methods.
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Materials and Methods
Materials

All reagents of highest purity were purchased from Sigma Chemical Company (St. Louis,
MO) unless otherwise noted. Human plasma was donated by the U.S. Army Materials
Command (Fort Detrick, MD). Human plasma fibrinogen depleted of fibronectin,
plasminogen, and von Willebrand Factor was purchased from Enzyme Research
Laboratories (South Bend, IN). Recombinant human thrombin (rFIIa) was purchased
from ZymoGenetics, Inc. (Seattle, WA). Human FXIII was bought from Enzyme
Research Laboratories. Human α2-AP was obtained from Haematologic Technologies
Inc. (Essex Junction, VT). Anti-mouse fibronectin monoclonal IgG1 antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-human FXIIIB
monoclonal antibody was purchased from Green Mountain Antibodies (Burlington, VT).
Anti-human FXIIIA polyclonal antibody was bought from US Biologicals. Anti-human
α2AP polyclonal antibody HRP was bought from US Biologicals. Anti-mouse IgG (whole
molecule) peroxidase conjugate and anti-sheep IgG peroxidase conjugate were obtained
from Sigma Chemical Company. Activated recombinant human factor XIII was purified
in our lab. Thromboelastography (TEG) disposable cups and pins were bought from
Haemoscope (Niles, IL).
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Frozen Plasma
Thaw at 4 °C
Centrifugation
(Cryoprecipitate)

Resuspension

Virus inactivation (0.3% TNBP and 1% Tween 80) or
(0.15% TNBP and 0.5% Triton x-100)

First ammonium sulfate precipitation

First ethanol Precipitation

Centrifugation

Centrifugation

Resuspension

Resuspension

Second ammonium sulfate precipitation

Second ethanol precipitation

Centrifugation

Centrifugation

Resuspension

Resuspension

Dialysis

Dialysis

Purified Fibrinogen solution

Figure 2: Fibrinogen purification procedure

Purified Fibrinogen solution
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Preparation of Cryoprecipitate

Fifteen units of human plasma (12.65 liters) frozen at -80 °C were thawed slowly
for two days at 4 °C. The resulting mixture was centrifuged in a Sorvall RC-5C Plus
Superspeed Centrifuge (Kendro Laboratory, Newtown, CT) at 4000 rpm for 20 min at 4
°C. The supernatant was stored at -80 °C for future fibronectin purification. The
fibrinogen-rich cryoprecipitate was re-suspended in a re-suspension buffer containing 20
mM tris-base, 55 mM sodium citrate, 27 mM lysine, PH 6.8. The solution was stirred
overnight at room temp. Viral inactivation was carried out using two different types of
solvent detergent. Part of the re-suspended cryoprecipitate was adjusted to 0.3% (V/V)
TNBP and 1% (V/V) Tween 80 while the other portion was subjected to 0.15% (V/V)
TNBP and 0.5% (V/V) Triton X-100 and the two solutions were stirred overnight at
room temp.
Ethanol Precipitation

Ethanol precipitation method was conducted by slightly modifying a previously
described method [52]. Briefly, the two types of solvent detergent treated solutions were
cooled to ~4 °C on ice then adjusted to 10% ethanol. Samples were incubated on ice
overnight then centrifuged in a Sorvall RC-5C Plus Superspeed Centrifuge at 4000 rpm at
4 °C for 20 min. The supernatant was discarded and the pellet was solubilized in resuspension buffer. A second 10% ethanol precipitation step was carried out at ~4 °C for
two hours on ice. The resulting pellet was solubilized in re-suspension buffer then
dialyzed versus dialysis buffer containing 20 mM sodium citrate, 100 mM sodium
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chloride, PH 7.4 at room temp. The dialyzed protein was collected and centrifuged for 20
min at 4000 rpm at 25 °C. Purified fibrinogen was stored in aliquots at - 80 °C.
Ammonium Sulfate Precipitation

The virally-inactivated cryo solutions were chilled to ~4 °C on ice then adjusted
to 1 M ammonium sulfate by adding a 4 M stock solution. Samples were incubated on ice
overnight then centrifuged at 4000 rpm at 4 °C for 20 min. The precipitate was resuspended in re-suspension buffer at room temp then chilled to ~4 °C on ice. A second
ammonium sulfate precipitation was done and the pellet was solubilized in re-suspension
buffer then dialyzed against dialysis buffer. The isolated protein was centrifuged for 20
min at 4000 rpm at 25 °C then frozen at -80 °C.
BCA Standard and Spectrophotometry

Total protein concentration was determined by spectrophotometric measurement
at 280 nm as well as BCA Standard procedure using bovine serum albumin as standard.
Evaluating Purified pdFI by SDS-PAGE

The purity of the isolated fibrinogen was examined by sodium dodecylsulfatepolyacrylamide (SDS-PAGE) gel electrophoresis. Samples were analyzed on 4-12%
NuPAGE Bis-Tris Mini Gels (Life Technologies, Carlsbad, CA) under reducing
condition. Samples were treated with SDS sample buffer and reducing agent, both
obtained from Invitrogen (Carlsbad, CA). After 10 minutes incubation at 74 °C, samples
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were loaded onto the gel and run using 2-(N-morpholino) ethanesulfonic acid (MES) for
one hour at 200 volts. Gels were stained with colloidal blue (Invitrogen, Carlsbad, CA).
Evaluating Clottability of pdFI by Thromboelastography

Thromboelastography (TEG) Hemostasis system 5000 series (Haemoscope
Corporation, Niles, IL) was used to evaluate the ability of purified fibrinogen to form a
clot. pdFI (concentrations of 9 or 4.5 mg/ml) were placed in a TEG cup, which is kept at
37oC by the instrument. rFXIIIa (concentration of 0.36 mg/ml) was added. CaCl2
(concentration of 12 mM) and Ringer solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl 2,
and 1 mM MgCl2) were added followed immediately by rFIIa (concentration of 105.6
U/ml) to trigger clot formation. The TEG analyzer collected clot parameters such as the
time to reach 2 mm clot strength (R), the time to reach 20 mm clot strength (K), and the
maximum clot strength (MA) every five seconds for 30 minutes. The data was collected
and analyzed in Microsoft Excel.
Estimating pdFXIIIA, pdFXIIIB, α2-AP, and pdFN by Western Blot

The contents of pdFXIIIA, pdFXIIIB, α2-AP, and pdFN on the isolated fibrinogen
were estimated by quantitative western blot analysis. Samples were analyzed on 4-12%
NuPAGE Bis-Tris Mini Gels (Life Technologies, Carlsbad, CA) under reducing or nonreducing condition. Gels were electroblotted onto polyvinylide fluoride (PVDF)
membranes (Millipore, Billerica, MA) for 30 min at 25 volts. Blots were blocked in 50
ml 5% casein in TBST then incubated for 30 minutes with the following antibodies: (a)
anti-human FXIIIA polyclonal antibody (US Biologicals, Swampscott, MA), (b) anti-
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human FXIIIB monoclonal antibody (Green Mountain Antibodies, Burlington, VT), (c)
anti-human α2AP polyclonal antibody HRP (US Biologicals), (d) anti-mouse fibronectin
monoclonal IgG1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Blot developed
with anti-human FXIIIA polyclonal antibody was subsequently detected with anti-sheep
IgG peroxidase conjugate (Sigma). Blots developed with anti-human FXIIIB monoclonal
antibody and anti-mouse fibronectin monoclonal IgG1 antibody were probed with antimouse IgG peroxidase conjugate (Sigma). Blots were visualized with DAB/Metal
concentrate and stable peroxide substrate buffer (Thermo Scientific, Rockford, IL) or
chemiluminescence using Immun-Star HRP enhancer and peroxide buffer (Bio-Rad
Laboratories, Hercules, CA). The quantity of pdFXIIIA, pdFXIIIB, pdFN, and α2-AP
were determined from the immunoblot of each material using Imagej (National Institute
of Health) or Adobe Photoshop Elements (Adobe Systems Incorporated).

Results
Evaluating Purified pdFI by SDS-PAGE

SDS-PAGE analysis [Fig 3] conducted under reducing condition showed that
pdFI purified by cryoprecipitation (lane 5), first ethanol precipitation (lane 6), second
ethanol precipitation (lane 7), first ammonium sulfate precipitation (lane 8), and second
ammonium sulfate precipitation (lane 9) all exhibit three distinct bands with apparent
molecular weights of ~67, 54, 47 kDa likely corresponding to the well-established α, β,
and γ chains of fibrinogen. Lanes 5, 6, 7, 8, and 9 also revealed a minor band at higher
molecular weight of ~220 kDa characteristic of fibronectin monomer. pdFI isolated by
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ethanol and ammonium sulfate precipitation contain two faint bands at ~80 and 120 kDa.
In addition to the bands at ~80 and 120 kDa, pdFI purified by cryoprecipitation possesses
additional faint bands.
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Figure 3: Reduced gel evaluation of purified pdFI.
Samples were analyzed on 4-12% SDS-PAGE and stained with
colloidal blue. Lane 1 is molecular weight marker. Lane 2 is human
fibrinogen (Enzyme Research). Lane 3 is human fibronectin (Enzyme
Research). Lane 4 is blank. Lane 5 is pdFI purified by cryoprecipitation.
Lanes 6 and 7 are pdFI purified by first and second AS precipitation,
respectively. Lanes 8 and 9 are pdFI purified by first and second EtOH
precipitation, respectively.
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Evaluating Clottability of pdFI by Thromboelastography

The viscoelastic and mechanical properties of clot formed by plasma fibrinogen
purified by cryoprecipitation, ethanol, and ammonium sulfate precipitation were
evaluated by thromboelastography [Fig 4]. It took 10 seconds to initiate clot formation
after rFIIa was added to pdFI isolated by cryoprecipitation, ethanol, and ammonium
sulfate precipitation [Table 6]. The maximal strength of clot developed by pdFI purified
by the first ethanol precipitation (1x) was 3267.70 ± 9.05 dynes/sec compared to 3278.9
± 829.58 dynes/sec for clot formed by pdFI purified by the second ethanol precipitation
(2x). pdFI isolated by the second ammonium sulfate precipitation (2x) resulted in clot
with maximal strength of 5811.7 ± 139.44 dynes/sec whereas pdFI purified by the first
ammonium sulfate precipitation (2x) formed clot with maximal strength of 2483.75 ±
167.09 dynes/sec. Clot developed from pdFI purified by the second ammonium sulfate
precipitated fibrinogen has the highest maximal strength (5811.7 ± 139.44). Clot
formation was inhibited in the solvent detergent (TNBP and Triton X-100) treated pdFI
purified by a single ammonium sulfate precipitation (Fig 5).
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Figure 4: Thromboelastography analysis of the clottability of isolated
fibrinogen. Change in maximal strength of clot developed by pdFI (4.5 mg/ml) activated
by rFIIa (105.6 U/ml) was recorded over time.

Table 6: Parameters of clot formed by purified fibrinogen
R
K
Angle
Protein
(sec) (sec)
(deg)
pdFI (Enzyme Research)
10
50
84.2
pdFI Purified By EtOH Precipitation (1x) 10
50
83.7
pdFI Purified By AS Precipitation (1x)
10
50
82.9
pdFI Purified By EtOH Precipitation (2x) 10
50
83.0
pdFI Purified By AS Precipitation (2x)
10
50
85.5
pdFI Purified By Cryoprecipitation
-2825 -225
-26.5

MA
(mm)
43.3
39.6
33.2
39.3
53.8
-2.2

G (d/sc)
3822.53
3267.70
2483.75
3278.9
5811.7
-110.6
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Figure 5: Thromboelastography analysis of the clottability of fibrinogen
purified by a single ammonium sulfate precipitation. Clot was formed by treating
plasma fibrinogen (9 mg/ml) with thrombin (105.6 U/ml).

Estimating Amounts of pdFXIIIA by Densitometry

Anti-human FXIIIA western blot analysis was conducted to estimate the
percentage of FXIIIA in pdFI isolated by the three purification techniques [Fig 6]. pdFI
purified by cryoprecipitation (lane 6), ammonium sulfate precipitation (lane 7), and
ethanol precipitation (lane 8) show bands corresponding to the known molecular weight
of pdFXIIIA. Using densitometry by Imagej, the percentages of FXIIIA in pdFI purified
by cryoprecipitation, ethanol, and ammonium sulfate precipitation were 0.652%, 0.781%,
and 0.683% respectively.

29

188
98
62
49
38
28
14

1

2

3

4

5

6

7

8

Figure 6: Western blot and densitometry by Imagej analysis of pdFXIIIA.
Samples were analyzed under non-reducing condition then developed with anti-FXIIIA Pab
and detected with anti-sheep IgG Peroxidase. Lane 1 is molecular weight marker. Lanes 2, 3,
4, and 5 are 0.063, 0.125, 0.25, and 0.5 µg purified pdFXIII respectively. Lane 6 is pdFI
purified by cryoprecipitation. Lane 7 is pdFI purified by ammonium sulfate precipitation. Lane
8 is pdFI purified by ethanol precipitation.

Standard

pdFXIIIA
(µg)
0.063
0.125
0.25
0.5

Area

Std Dev

2448.966
11938.687
22682.825
36268.311

25.7
30.6
41.5
32.0

Standard Curve
40000
35000
30000

m =
b =

Area

25000

73605
1074.4

20000
15000
y = 73605x + 1074.4
R² = 0.9585

10000

5000
0
0

Purification Method
pdFXIIIA (Cryoprecipitation)
pdFXIIIA (AS Precipitation)
pdFXIIIA (EtOH Precipitation)

Area

Std Dev

25056.405
26209.172
29808.28

35.0
25.8
38.8

0.1

pdFXIIIA pdFI Loaded
pdFXIIIA/pdFI
(µg)
(µg)
0.32582
0.34148
0.39038

50
50
50

0.00652
0.00683
0.00781

0.2

0.3
0.4
pdFXIIIA (µg)

0.5

0.6

30
Estimating Amounts of pdFXIIIB by Densitometry

The amounts of FXIIIB in pdFI precipitated by the three purification methods
were calculated from the anti-human FXIIIB western blot analysis [Fig 7]. pdFI isolated
by cryoprecipitation (lane 7), ammonium sulfate precipitation (lane 8), and ethanol
precipitation (lane 9) show a band characteristic of the known molecular weight of
pdFXIIIB. Densitometric measurement of the bands revealed that cryoprecipitation,
ammonium sulfate, and ethanol precipitation pdFI contain 0.329%, 0.809%, and 0.481%
respectively.
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Figure 7: Western blot and densitometry by Imagej analysis of pdFXIIIB.
Samples were analyzed under non-reducing condition and developed with anti-FXIIIB
Mab then detected with anti-mouse IgG peroxidase. Lane 1 is molecular weight marker.
Lanes 2, 3, 4, and 5 are 0.063, 0.125, 0.25, and 0.5 µg purified pdFXIII respectively.
Lane 6 is blank. Lane 7 is pdFI purified by cryoprecipitation. Lane 8 is pdFI purified by
ammonium sulfate precipitation. Lane 9 is pdFI purified by ethanol precipitation.
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Estimating Amounts of α2-AP by Densitometry

The content of α2-AP in the purified pdFI was determined by anti-human α2AP
western blot analysis [Fig 8]. pdFI isolated by cryoprecipitation (lane 6), ammonium
sulfate (lane 7), and ethanol (lane 8) precipitation exhibit a minor band at ~62 kDa
representing the molecular weight of α2-AP. By employing densitometry, pdFI purified
by cryoprecipitation, ammonium sulfate, and ethanol precipitation contain 0.184%,
0.493%, and 0.254% α2-AP.
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Figure 8: Western blot and densitometry by Imagej analysis of α2-AP.
Samples were analyzed under reducing condition and developed with anti- α2AP Pab
HRP. Lane 1 is molecular weight marker. Lanes 2, 3, 4, and 5 are 0.013, 0.025, 0.05,
and 0.1 µg purified α2-AP respectively. Lane 6 is pdFI purified by cryoprecipitation.
Lane 7 is pdFI purified by ammonium sulfate precipitation. Lane 8 is pdFI purified by
ethanol precipitation.
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Estimating Amounts of pdFN by Densitometry

Anti-human FN western blot analysis was done to estimate the quantity of FN
purified with pdFI [Fig 9]. pdFI purified by cryoprecipitation (lane 7), ammonium sulfate
(lane 8), and ethanol precipitation (lane 9) show bands at ~220 kDa corresponding to
fibronectin monomer. Densitometry by Adobe Photoshop Elements was employed to
calculate the percentage of FN in pdFI isolated by cryoprecipitation (3.18%), ammonium
sulfate precipitation (8.09%), and ethanol precipitation (3.98%).
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Figure 9: Western blot and densitometry by Imagej analysis of pdFN.
Samples were analyzed under reducing condition and developed with anti-mouse
fibronectin monoclonal IgG1 then detected with anti-mouse IgG peroxidase. Lane
1 is molecular weight marker. Lanes 2, 3, 4, and 5 are 0.25, 0.5, 1, and 2 µg
purified pdFN respectively. Lane 6 is blank. Lane 7 is pdFI purified by
cryoprecipitation. Lane 8 is pdFI purified by ammonium sulfate precipitation. Lane
9 is pdFI purified by ethanol precipitation.
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DISCUSSION
Various approaches have been developed to isolate fibrinogen from plasma
sources. These methods include cryoprecipitation, centrifugation, ultrafiltration,
chromatography, and chemical precipitation. We isolated a solvent detergent treated
fibrinogen from human plasma using cryoprecipitation followed by ammonium sulfate or
ethanol precipitation. Fibrinogen isolated by the three purification methods is highly
pure. To determine the effectiveness of purified plasma fibrinogen to form clots, we
measured clottability of fibrinogen using thromboelastography. Our study showed that
clot formed from plasma fibrinogen produced by the repeated ammonium sulfate
precipitation has the highest maximal strength.
Based on the purification method, fibrinogen removed from plasma contains
various amounts of fibronectin, factor XIII, alpha2-antiplasmin, plasminogen, and other
plasma proteins. We estimated the quantities of fibronectin, factor FXIIIA, factor FXIIIB,
and α2-AP in the plasma fibrinogen isolated by three purification procedures. Plasma
fibrinogen obtained by ammonium sulfate precipitation was found to contain increased
ratios of FXIIIA, FXIIIB, FN, and α2-AP to fibrinogen than the starting cryoprecipitate.
Plasma fibrinogen from ethanol precipitation also contains higher ratios of FXIIIA,
FXIIIB, α2-AP, and FN to fibrinogen than the original cryoprecipitate. This indicates that
chemical precipitation may preserve the binding of FXIIIA, FXIIIB, FN, and α2-AP to
fibrinogen during the purification process.
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Viral inactivation was achieved by using two different types of solvent detergent
mixtures: (1) 0.3% TNBP and 1% Tween 80, (2) 0.15% TNBP and 0.5% Triton X-100.
Since the presence of solvent detergent inhibits clot formation, we utilized
thromboelastography to evaluate the effectiveness of ethanol and ammonium sulfate
precipitation to remove the solvent detergent. While purifying a solvent detergent treated
fibrinogen from human plasma, Burnouf-Radosevich et al [52] applied a second ethanol
precipitations to further remove the solvent detergent. However, we showed that clots
formed from fibrinogen isolated by first and second ethanol precipitation have similar
maximal strength. This indicates that a single ethanol precipitation step is capable of
eliminating the solvent detergent. A single ammonium sulfate precipitation partially
removed the mixture 0.3% TNBP and 1% Tween 80 but not the mixture 0.15% TNBP
and 0.5% Triton x-100. Thus, a second ammonium sulfate precipitation is required for the
complete elimination of the solvent detergent mixture TNBP and Triton X-100.
Together the data presented in this thesis indicate that the combination of
cryoprecipitation and successive ammonium sulfate precipitations results in the
fibrinogen with the strongest clot forming activity. The bases for the increased strength
has not been determined but is likely due to the increased ratios of associated proteins,
particularly fibronectin in the ammonium sulfate derived material.

37

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

15.
16.

17.

18.
19.
20.

Galina Tsurupa; Latchezar Tsonev; Leonid Medved. Structural Organization
of the Fibrin(ogen) αC-Domain. Biochemistry 41: 6449-6459 (2002).
Henschen A; Lottspeich F; Kehl M; Southan C. Covalent structure of fibrinogen
Ann N Y Acad Sci 408: 28–43 (1983).
Privalov PL; Medved LV. J Mol Biol 159: 665-683 (1982).
Medved LV; Litvinovich S; Ugarova T; Matsuka Y; Ingham K.
Biochemistry 36: 4685-4693 (1997).
Medved LV; Gorkun OV; Privalov PL. FEBS Lett 160: 291-295 (1983).
Doolittle RF; Annu Rev. Biochem 53:195-229 (1984).
Brown JH; Volkmann N; Jun G; Henschen-Edman AH; Cohen C. Proc Natl
Acad Sci USA 97: 85-90 (2000).
Weisel JW; Stauffacher CV; Bullitt E; Cohen C. Science 230: 1388-1391 (1985).
McKee P.A; Rogers L.A; Marler E; Hill R.L. Arch. Biochem. Biophys. 1966; 116,
271-279.
Doolittle RF. Thromb Haemost (Bloom AL; Thomas DP, eds) 163-197 (1981),
Churchill Living-stone, Edinburgh.
Townsend RR; Hilliker E; Li YT; Laine RA; Bell WR; Lee YC. J Biol Chem 257:
9704-9710 (1982).
Finlayson JS; Mosesson MW. Heterogeneity of human fibrinogen. Biochemistry
2: 42-46 (1963).
Mosesson MW; Finlayson JS; Umfleet RA. Human fibrinogen heterogeneities,
III: identification of γ-chain variants. J Biol Chem. 247: 5223-5227 (1972).
Wolfenstein-Todel C; Mosesson MW. Human plasma fibrinogen heterogeneity:
evidence for an extended carboxyl-terminal sequence in a normal gamma chain
variant ( ). Proc Natl Acad Sci USA 77: 5069-5073 (1980).
Chung DW; Davie EW. and
chains of human fibrinogen are produced by
alternative mRNA processing. Biochemistry 23:4232-4236 (1984).
Farrell DH; Mulvihill ER; Huang SM; Chung DW; Davie EW. Recombinant
human fibrinogen and sulfation of the gamma chain. Biochemistry 30:9414-9420
(1991).
Stathakis N.E.; M.W. Mosesson. Interactions among heparin, cold-insoluble
globulin, and fibrinogen in formation of the heparin precipitable fraction of
plasma. J. Clin. Invest. 60: 855–865 (1977).
Sahni A.; T. Odrljin; C.W. Francis. Binding of basic fibroblast growth factors to
fibrinogen and fibrin. J. Biol. Chem. 273: 7554–7559 (1998).
Loscalzo J.; M. Weinfeld; G.M. Fless; A.M. Scanu. Lipoprotein(a), fibrin
binding, and plasminogen activation. Arteriosclerosis 10: 240–245 (1990).
Hervio L.; V. Durlach; A. Girard-Globa; E. Angles-Cano. Multiple binding with
identical linkage: a mechanism that explains the effect of lipoprotein(a) on
fibrinolysis. Biochemistry 34: 13353–13358 (1995).

38

21.
22.

23.

24.

25.

26.
27.

28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.

39.

40.

Meh D.A.; K.R. Siebenlist; M.W. Mosesson. Identification and characterization
of the thrombin binding sites on fibrin. J. Biol. Chem. 271: 23121–23125 (1996).
Bok R.A.; W.F. Mangel. Quantitative characterization of the binding of
plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by
plasmin. Biochemistry 24: 3279–3286 (1985).
Spraggon G; Everse SJ; Doolittle RF. Crystal structures of fragment D from
human fibrinogen and its crosslinked counterpart from fibrin. Nature 389:455-462
(1997).
Weisel JW; Francis CW; Nagaswami C; Marder VJ. Determination of the
topology of factor XIIIa induced fibrin gamma-chain cross-links by electron
microscopy of ligated fragments. J Biol Chem. 268:26618-26624 (1993).
Purves L; Purves M; Brandt W. Cleavage of fibrinderived D-dimer into
monomers by endopeptidase from puff adder venom (Bitis arietans) acting at
cross-linked sites of the gamma-chain: sequence of carboxy-terminal cyanogen
bromide gamma-chain fragments. Biochemistry 26: 4640-4646 (1987).
Tamaki T.; H. Aoki. Cross-linking of α2-plasmin inhibitor and fibronectin to
fibrin by fibrin-stabilizing factor. Biochim. Biophys. Acta 661: 280–286 (1981).
Michael S. Kostelansky; Karim C. Lounes; Li Fang Ping; Sarah K. Dickerson;
Oleg V. Gorkun; Susan T. Lord. Calcium-Binding Site β2, Adjacent to the ‘b’
Polymerization Site, Modulates Lateral Aggregation of Protofibrils during Fibrin
Polymerization. Biochemsitry 34, 2475-2483 (2004).
Fornace A.J. Jr.; Cummings D.E.; Comeau C.M.; Kant J.A.; Crabtree G.R. J.
Biol. Chem. 259: 12826 (1984).
Hortin G.L. Biochem. Int. 19: 1355 ( 1989).
Heldin P.; Hessel B.; Humble E.; Blomback B.; Engstrom L. Thromb. Res. 47: 93
(1987).
Dang C.V.; Shin C.K.; Bell W.R.; Nagaswami C.; Weisel J.W. J. Biol. Chem.
264: 5104 (1989).
Francis C.W.; Keele E.M.; Marder V.J. Biochim. Biophys. Acta 797: 328 (1984).
De Maat MPM; Verschuur M; Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 12: 377-83 (2005).
Henschen A.H. Thromb. Haemost. 70: 42 (1993).
Olexa SA; Budzynski AZ. Proc. Natl. Acad. Sci.U.S.A. 77: 1374-8 (1980).
Everse SJ; Spraggon G; Veerapandian L; Riley M; Doolittle RF. Biochemistry 37:
8637-8642 (1998).
Mosesson MW; Siebenlist KR; Hainfeld JF; Wall JS. The covalent structure of
factor XIIIa crosslinked fibrinogen fibrils. J Struct Biol 115: 88–101(1995).
Siebenlist KR; Meh D; Mosesson MW. Protransglutaminase (factor
XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 86: 1221–
8 (2001).
McKee PA; Mattock P; Hill RL. Subunit structure of human fibrinogen, soluble
fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci USA 66: 738–44
(1970).
Kanaide H; Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrinstabilizing factor (factor XIIIa). J LabClinMed 85: 574–97 (1975).

39

41.
42.
43.
44.

45.
46.
47.
48.
49.
50.

51.

52.
53.

54.
55.

56.
57.

58.
59.
60.

Doolittle RF; Chen R; Lau F. Hybrid fibrin: proof of the intermolecular nature of
c-c-crosslinking units. Biochem Biophys Res Commun 44: 94–100 (1971).
Chen R; Doolittle RF. c-c-Cross-linking sites in human and bovine fibrin.
Biochemistry 10: 4486–91(1971).
Siebenlist KR; Mosesson MW. Evidence for intramolecular crosslinked αc chain
heterodimers in plasma fibrinogen. Biochemistry 35: 5817–21(1996).
Wan H.L.; S T. Huang; D M. Floyd; D H. Sierra. Is the amount of fibrinogen in
cryoprecipitate is adequate for fibrin glue? Introducing an improved recycle
cryoprecipitate method. Transfusion 29: 41 (1989).
Park M.S.; C.I. Cha. Biochemical aspects of autologous fibrin glue derived from
ammonium sulfate precipitation. Laryngoscope 103(2): 193-6 (1993).
Blombaeck B.; Blombaeck M. Purification of human and bovine fibrinogen.
Arkiv. Kemi. 10: 415–443 (1956).
Straughn W.; Wagner R.H. A simple method for preparing fibrinogen. Thromb.
Diath. Haematol. 16: 198–206 (1966).
Keckwick R.A.; Mackay M.E.; Nance M.H. The purification of human
fibrinogen. Biochem. J. 60: 671–678 (1955).
Laki K. The polymerization of proteins: the action of thrombin on fibrinogen.
Arch. Biochem. Biophys. 32: 317–324 (1951).
Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P;
Jitpraphai C; Hathirat P; Nuchprayoon C. The efficacy and safety of lyophilized
cryoprecipitate in hemophilia A. J Med Assoc Thai 82: S69–S73 (1999).
Hornsey VS; Krailadsiri P; MacDonald S; Seghatchian J; Williamson LM;
Prowse CV. Coagulation factor content of cryoprecipitate prepared from
methylene blue plus light virusinactivated plasma. Br J Haematol 109:665–670
(2000).
M. Burnouf-Radosevich, T. Burnouf, J. J. Huart. Biochemical and physical
properties of a solvent-detergent-treated fibrin glue. Vox Sang 58: 77-84 (1990).
Bernard Horowitz; Richard Bonomo; Alfred M. Prince; Sing N. Chin; Betsy
Brotman; Richard W. Shulman. Solvent/Detergent-Treated Plasma: A VirusInactivated Substitute for Fresh Frozen Plasma. Blood 79: 826-831 (1992).
Muszbek L; Yee VC; Hevessy Z. Thromb. Res. 94: 271 (1999).
Greenberg CS; Sane DC; Lai T; Colman RW; Marder VJ; Clowes AW; George
JN; Goldhaber SZ. Eds; Lippincott Williams; Wilkins: Philadelphia, Hemostasis
and Thrombosis, 5th edn. pp.153-81 (2006).
Brian T; Turner Jr; Muriel C. Maurer. Biochemistry 41: 7947-7954 (2002).
Bishop PD; Teller DC; Smith RA; Lasser GW; Gilbert T; Seale RL. Expression,
Purification, and characterization of human factor XIII in Saccharomyces
cerevisiae. Biochemistry 29: 861-9 (1990).
Carrell NA; Erickson HP; McDonagh J. Electron microscopy and hydrodynamic
properties of factor XIII subunits. J Biol Chem 264: 551-6 (1989).
Jan McDonagh. Structure and function of factor XIII. Hemost and Thromb,1994.
Schwartz ML; Pizzo SV; Hill RL; McKee PA. Human factor XIII from plasma
and platelets. Molecular weights, subunit structures, proteolytic activation, and
cross-linking of fibrinogen and fibrin. J Biol Chem 248:1395 (1973).

40

61.

62.

63.

64.
65.
66.

67.

68.
69.
70.

71.
72.

73.

74.
75.

76.
77.
78.

Mary A, Achyuthan KE, Greenberg CS. B-chains prevent the proteolytic
inactivation of the a-chains of plasma factor XIII. Biochim Biophys Acta 966: 328
(1988).
Katona E; Haramura G; Karpati L; Fachet J;Muszbek L. A simple, quick one-step
ELISA assay for the determination of complex plasma factor XIII (A2B2).
Thromb Haemost 83: 268–73 (2000).
Ichinose A.; McMullen B. A.; Fujikawa K.; Davie E. W. Amino acid sequence of
the B subunit of human Factor XIII, a protein composed of ten repetitive
segments. Biochemistry 25: 4633–4638 (1986).
Ichinose A.; Bottenus R. E.; Davie E. W. Structure of transglutaminase. J. Biol.
Chem. 265: 13411–13414 (1990).
Nagy JA, Kradin RL, McDonagh J. Biosynthesis of factor XIII A and B subunits.
Adv Exp Med Biol.231: 29-49 (1988).
Weisberg L.J.; Shiu DT; Conkling PR; Shuman MA. Identification of normal
human peripheral blood monocytes and liver as sites of synthesis of coagulation
factor XIII a-chain. Blood 70: 579-582 (1987).
A´ da´ny R; Nemes Z; Muszbek L. Characterization of factor XIII containingmacrophages in lymph nodes with Hodgkin’s disease. Br J Cancer 55: 421-426
(1987).
Lozier J.; Takahashi N.; Putnam F. W. Complete amino acid sequence of human
plasma b2-glycoprotein I. Proc. Natl. Acad. Sci. U.S.A. 81: 3640–3644 (1984).
Weiss M.S.; Metzner HJ; Hilgenfeld R. Two non-proline cis peptide bonds may
be important for factor XIII function. FEBS Lett. 423: 291-296 (1998).
Schwartz M.l.; Pizzo SV; Hill RL; McKee PA. The subunit structure of human
plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem. 246: 58515854 (1971).
Henriksson T.H.; Becker S; McDonagh J: Identification of intracellular factor
XIII in human monocytes and macrophages. J Clin Invest 76:528 (1985).
Kiesselbach T.H.; Wagner RH: Demonstration of factor XIII in human
megakaryocytes by a flurorescent antibody technique. Ann NY Acad Sci 202: 318
(1972).
Yee V.C.; Pedersen LC; Bishop PD; Stenkamp RE; Teller DC. Structural
evidence that the activation peptide in not released upon thrombin cleavage of
factor XIII. Thromb Res 78:389-97 (1995).
Grundman U; Amann E; Zettlmeissl G; Kupper HA: Characterization of a cDNA
coding for human factor XIIIa. Proc Natl Acad Sci USA 83:8024 (1986).
Schroeder V; Vuissoz JM; Caflisch A; Kohler HP. Factor XIII activation peptide
is released into plasma upon cleavage by thrombin and showed a different
structure compared to it is bound form. Thromb Haemost 97: 890-8 (1993).
Hornyak T.J.; Shafer JA. Role of calcium ion in the generation of factor XIII
activity. Biochemistry 30: 6175–82 (1991).
Lewis S.D.; Janus TJ; Lorand L; Shafer JA. Regulation of formation of factor
XIIIa by its fibrin substrates. Biochemistry 24: 6772–7 (1985).
Sakata Y; Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrinstabilizing factor. J Clin Invest.65: 290-297 (1980).

41

79.
80.
81.

82.

83.

84.

85.

86.
87.
88.

89.

90.

91.
92.

93.
94.
95.

Kimura S; Aoki N. Cross-linking site in fibrinogen for alpha2-plasmin inhibitor. J
Biol Chem. 261: 15591-15595 (1986).
Kimura S; Tamaki T; Aoki N. Acceleration of fibrinolysis by the N-terminal
peptide of alpha 2-plasmin inhibitor. Blood 66: 157-160 (1985).
Cottrell B.A.; Strong DD; Watt KW; Doolittle RF. Amino acid sequence studies
on the α-chain of human fibrinogen: exact location of cross-linking acceptor sites.
Biochemistry 18: 5405-5410 (1979).
Fretto L.J.; Ferguson EW; Steinman HM; McKee PA. Localization of the alphachain cross-link acceptor sites of human fibrin. J Biol Chem. 253: 2184-2195
(1978).
Matsuka Y.V.; Medved LV; Migliorini MM; Ingham KC. Factor XIIIa-catalyzed
cross-linking of recombinant αC fragments of human fibrinogen. Biochemistry
35: 5810-5816 (1996).
Mosher D.F.; Schad PE; Vann JM. Cross-linking of collagen and fibronectin by
factor XIIIa: localization of participating glutaminyl residues to a tryptic fragment
of fibronectin. J Biol Chem. 255: 1181-1188 (1980).
Procyk R; Adamson L; Block M; Blomback B. Factor XIII catalyzed formation of
fibrinogen-fibronectin oligomers: a thiol enhanced process. Thromb Res. 40: 833852 (1985).
Mosher D.F.; Schad PE. Cross-linking of fibronectin to collagen by blood
coagulation factor XIIIa. J Clin Invest. 64: 781-787 (1979).
Hada M; Kaminski M; Bockenstedt P; McDonagh J. Covalent crosslinking of von
Willebrand factor to fibrin. Blood 68: 95-101(1986).
Bockenstedt P; McDonagh J; Handin RI. Binding and covalent cross-linking of
purified von Willebrand factor to native monomeric collagen. J Clin Invest. 78:
551-556 (1986).
Sane D.C.; Moser TL; Pippen AM; Parker CJ; Achyuthan KE; Greenberg CS.
Vitronectin is a substrate for transglutaminases. Biochem Biophys Res
Commun.157:115-120 (1988).
Skorstengaard K; Halkier T; Hojrup P; Mosher D. Sequence location of a putative
transglutaminase cross-linking site in human vitronectin. FEBS Lett. 262: 269-274
(1990).
Francis R.T.; McDonagh J; Mann KG. Factor V is a substrate for the transamidase
factor XIIIa. J Biol Chem. 261: 9787-9792 (1986).
Huh M.M.; Schick BP; Schick PK; Colman RW. Covalent crosslinking of human
coagulation factor V by activated factor XIII from guinea pig megakaryocytes and
human plasma. Blood 71: 1693-1702 (1988).
Bale M.D.; Westrick LG; Mosher DF. Incorporation of hrombospondin
into fibrin clots. J Biol Chem. 260: 7502-7508 (1985).
Mui P.T.; Ganguly P. Cross-linking of actin and fibrin by fibrin-stabilizing factor.
Am J Physiol. 233: H346-H349 (1977).
Cohen I; Blankenberg TA; Borden D; Kahn DR; Veis A. Factor XIIIa-catalyzed
cross-linking of platelet and muscle actin: regulation by nucleotides. Biochim
Biophys Acta. 628: 365-375 (1980).

42

96.

97.

98.

99.
100.
101.

102.

103.
104.
105.

106.
107.
108.
109.
110.
111.
112.

113.

Valnickova Z; Enghild JJ. Human procarboxypeptidase U, or thrombin-activable
fibrinolysis inhibitor, is a substrate for transglutaminases: evidence
for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 273: 2722027224 (1998).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA. Cross-linking of
plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen). J Biol
Chem. 275: 24915-24920 (2000).
Ritchie H; Lawrie LC; Mosesson MW; Booth NA. Characterization of
crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2). Ann
N Y Acad Sci. 936: 215-218 (2001).
Mosesson M.W. Fibrinogen
chain functions. Thromb Heamost 1:231-238
(2002).
Greenberg C.S.; Miraglia CC. The effect of fibrin polymers on thrombincatalyzed plasma factor XIIIa formation. Blood 66: 466–9 (1985).
Greenberg C.S.; Achyuthan KE; Rajagopalan S; Pizzo SV. Characterization of the
fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
Arch Biochem Biophys 262: 142–8 (1988).
Naski M.C.; Lorand L; Shafer JA. Characterization of the kinetic pathway for
fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII.
Biochemistry 30: 934–41 (1991).
Janus TJ; Lewis SD; Lorand L; Shafer JA. Promotion of thrombin catalyzed
activation of factor XIII by fibrinogen. Biochemistry 22: 6269–72 (1983).
Hornyak TJ; Shafer JA. Interactions of factor XIII with fibrin as substrate and
cofactor. Biochemistry 31: 423–9 (1992).
Greenberg CS; Achyuthan KE; Fenton JW II. Factor XIIIa formation promoted by
complexing of alpha-thrombin, fibrin, and plasma factor XIII. Blood 69: 867–71
(1987).
Siebenlist KR; Meh DA; Mosesson MW. Plasma factor XIII binds specifically to
fibrinogen molecules containing chains. Biochemistry 35:10448-53 (1996).
Lynch GW; Pfueller SL. Thrombins-independent activation of platelet factor XIII
by endogenous platelet acid protease. Thromb Haemost 59:372-377 (1988).
Francis RT; McDonagh J; Mann KG. J. Biol. Chem 26: 9787(1986).
Jansen PH; Lorand L; Ebbesen P; Gliemann J. Eur. J.Biochem 214:141 (1993).
Bendixen E; Borth W; Harpel PC. J. Biol. Chem 268:21962 (1993).
Borth W; Chang V; Bishop P; Harpel PC. J. Biol. Chem 266: 18149 (1991).
Kangsadalampai S; Chelvanayagam G; Baker RT; Yenchitsomanus P; Pungamritt P; Mahasandana C; Board PG. A novel Asn344 deletion in the core domain
of coagulation factor XIII A subunit: Its effects on protein structure and function.
Blood 92: 481-7 (1998).
Koyama T; Koike Y; Toyota S; Miyagi F; Suzuki N; Aoki N. Different NH2terminal form with 12 additional residues of alpha 2-plasmin inhibitor from
human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun
200: 417–22 (1994).

43

114.
115.
116.
117.
118.

119.
120.

121.
122.

Bangert K; Johnsen AH; Christensen U; Thorsen S. Different N-terminal forms of
alpha 2-plasmin inhibitor in human plasma. Biochem J 291 (Pt 2): 623–5 (1993).
Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 272: 4852–7 (2005).
Aoki N. Genetic abnormalities of the fibrinolytic system. Semin Thromb Hemost
10: 42–50 (1984).
Collen D; Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of
plasma. Blood 53: 313–24 (1979).
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA. A novel plasma
proteinase potentiates α2-antiplasmin inhibition of fibrin digestion. Blood 103:
3783-3788 (2004).
Hirosawa S.; Nakamura Y.; Miura O.; Sumi, Y.; Aoki, N. Proc.Natl. Acad. Sci.
U.S.A. 85: 6836 (1988).
Sumi, Y; Nakamura Y; Aoki N; Sakai M; Muramatsu M. Structure of the
carboxyl-terminal half of human R2-plasmin inhibitor deduced from that of
cDNA. J. Biochem. 100: 1399–13402 (1986).
Pierschbacher MD; Ruoslahti E. Cell attachment activity of fibronectin can be
duplicated by small fragments of the molecule. Nature 309: 30-33 (1984).
Law R H; Sofian T; Kan WT; Horvath AJ; Hitchen CR; Langendorf CG; Buckle
AM; Whisstock JC; Coughlin PB. X-ray crystal structure of the fibrinolysis
inhibitor R2-antiplasmin. Blood 111: 2049–2052 (2008).

123.

Sasaki T; Morita T; Iwanaga S. Identification of the plasminogen-binding site of
human R2-plasmin inhibitor. J. Biochem. 99: 1699–1705 (1986).

124.

Frank PS; Douglas JT; Locher M Llin_as M; Schaller J. Structural/functional
characterization of the R2-plasmin inhibitor C-terminal peptide. Biochemistry 42:
1078–1085 (2003).
Aoki N; Harpel PC. Semin. Thromb. Hemostasis 10: 24-41 (1984).
Moroi M; Aoki N. J. Biol. Chem. 261: 5956-5965 (1976).
Aoki N; Moroi M; Tachiya K. Thromb. Haemstasis 39: 22-31 (1978).
Ichinose A; Koide T; Aoki N. Thromb. Res. 33: 401-407 (1984).
Sakata Y; Aoki N. J. Clin. Invest. 65: 290-297 (1980).
Sakata Y; Aoki N. J. Clin. Invest. 69: 536-542 (1982).
Tamaki T; Aoki N. J. Biol. Chem. 267: 14767-14772 (1982).
Wiman B; Boman L; Collen D. Eur. J. Biochem 87: 143 (1978).
Sasaki T; Morita T; Iwanaga S. J. Biochem. (Tokyo) 99: 1699 (1986).
Sasaki T; Sugiyama N; Iwamoto M; Isoda S. Chem. Pharm.Bull. (Tokyo) 35:
2810 (1987).
Wiman B; Collen D. Nature 272: 549-50 (1978).
Aoki N; Sakata Y; Ichinose A. Blood 62: 1118-1122 (1983).
Tamaki T; Aoki H. Cross-linking of a2-plasmin inhibitor and fibronectin to fibrin
by fibrin-stabilizing factor. Biochim Biophys Acta 661: 280–6 (1981).
Ichinose A; Aoki N. Reversible cross-linking of alpha 2-plasmin inhibitor to
fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 706: 158–64 (1982).

125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.

44

139.
140.

141.
142.
143.

144.

145.
146.
147.
148.
149.
150.
151.
152.

153.
154.
155.

156.
157.

158.
159.

Sakata Y; Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrinstabilizing factor. J Clin Invest 65: 290–7 (1980).
Ichinose A; Aoki N. Reversible cross-linking of alpha 2-plasmin inhibitor to
fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 706: 158–164
(1982).
Saito H. J. Lab. Clin. Med. 112: 671 (1988).
Favier R; Aoki N. de Moerloose, P. Br. J. Haematol. 114: 4 (2001).
Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee
PA. Evidence that α2-antiplasmin becomes covalently ligated to plasma
fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis
regulation. Thromb. And Heamos 6: 1565-1570 (2008).
Zardi L; Cecconi C; Barbieri O; Carnemolla B; Picca M; Santi L. Concentration
of fibronectin in plasma of tumor-bearing mice and synthesis by Ehrlich ascites
tumor cells. Cancer Res 39: 3774-3779 (1979).
Mao Y; Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix
assembly process. Matrix Biol 24: 389-399 (2005).
Mosesson M. W.; Chen A. B.; Huseby R. M. Biochim (1975).
Mosher D. F. J. Biol. Chem. 260: 6614-6621 (1985).
Kurkinen M.; Vartio T.; Vaheri, A. Biochim. Biophys. Acta 624: 490-498 (1980).
Furie M. B.; Rifkin D. B. J. Biol. Chem. 255: 3134-3140 (1980).
Skorstengaard K.; Thegersen H. C.; Vibe-Pedersen K.; Petersen I. E.; Magnusson
S. Eur. J. Biochem. 128: 605-623 (1982).
Odermatte; J. Engel. Physical properties of fibronectin. In Fibronectin. D. F.
Mosher, Ed.: 25-43. Academic Press. New York, NY (1989).
Petersen T. E.; Thogerson H. C.; Skorstengaard K.; Vibe-Pedersen K.; Sahl P.;
Sottrup-Jensen L.; Magnusson S. Proc. Natl. Acad. Sci.U. S. A. 80: 137–141
(1983).
Rocco M.; Carson N.; Hantgan R.; McDonagh J.; Hermans J. J. Biol. Chem. 258:
14545–14555 (1983).
Leahy D. J.; Aukhil I.; Erickson H. P. Cell 84: 155–164 (1996).
Deanef. Mosher; Ofrances J. Fogerty; Michael A.Chernousov; Elizabeth L; R.
Barry. Assembly of Fibronectin into Extracellular Matrix. Adhesive Proteins and
the Extracellular Matrix; Part V.
Hynes RO. Fibronectins Springer-Verlag, New York (1990).
Burns GF;C osgroveL; TrigliaT; BeallJ A; L6pezA F; Werk-meister JA; Begley
CG; Haddad AP; d'Apice AJF; Vadas MA; CawleyJ C. The IIb-IIIag lycoprotein
complext hat mediatesp lateleta ggregationis directlyim plicatedin leu-kocyte
adhesion. Cell 45: 269-80 (1986).
Mosher DF; Johnson RB. In vitro formation of disulfide-bonded fibronectin
multimers. J Biol Chem 258: 6595–6601 (1983).
Matsuka YV; Migliorini MM; Ingham KC. Cross-linking of fibronectin to Cterminal fragments of the fibrinogen α-chain by factor XIIIa. J Protein Chem16:
739–745 (1997).

45

160.

161.
162.

Makogonenko E; Tsurupa G; Ingham K; Medved L. Interaction of fibrin(ogen)
with fibronectin: further characterization and localization of the fibronectinbinding site. Biochemistry 41: 7907–7913 (2002).
Quade B. J.; McDonald J. A. J. Biol. Chem. 263: 19602-19609 (1988).
Patti J. M.; Allen B. L.; McGavin M. J.; Ho¨o¨k, M. Annu. ReV. Microbiol. 48:
585-617 (1994).

